Imunon (NASDAQ:IMNN – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.61) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 11:00 AM ET.
Imunon (NASDAQ:IMNN – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.33. On average, analysts expect Imunon to post ($2.37) EPS for the current fiscal year and ($2.03) EPS for the next fiscal year.
Imunon Price Performance
NASDAQ IMNN opened at $0.88 on Tuesday. Imunon has a 1 year low of $0.81 and a 1 year high of $4.38. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 2.86. The company’s 50 day simple moving average is $1.22 and its two-hundred day simple moving average is $2.16.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.
Read Our Latest Report on IMNN
About Imunon
Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.
Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.
Read More
- Five stocks we like better than Imunon
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
